1.Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014; 384(9957): 1878–88.
2.Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis research & therapy 2009; 11(5): 247.
3.Dorner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE. Arthritis research & therapy 2011; 13(5): 243.
4.Suarez-Fueyo A, Bradley SJ, Tsokos GC. T cells in Systemic Lupus Erythematosus. Current opinion in immunology 2016; 43: 32–8.
5.Schrezenmeier E, Weissenberg SY, Stefanski AL, et al. Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations. Current opinion in rheumatology 2019; 31(2): 175–84.
6.Wang LL, Li ZH, Hu XH, Muyayalo KP, Zhang YH, Liao AH. The roles of the PD–1/PD-L1 pathway at immunologically privileged sites. American journal of reproductive immunology 2017; 78(2).
7.Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity 2018; 48(3): 434–52.
8.Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nature reviews Immunology 2018; 18(3): 153–67.
9.Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity. Nature communications 2015; 6: 5997.
10.Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. Journal of immunology 2008; 181(4): 2513–21.
11.Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD–1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11(2): 141–51.
12.Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD–1 receptor-deficient mice. Science 2001; 291(5502): 319–22.
13.Ansari MJ, Salama AD, Chitnis T, et al. The programmed death–1 (PD–1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. The Journal of experimental medicine 2003; 198(1): 63–9.
14.Boussiotis VA. Molecular and Biochemical Aspects of the PD–1 Checkpoint Pathway. The New England journal of medicine 2016; 375(18): 1767–78.
15.Zhang Q, Vignali DA. Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity 2016; 44(5): 1034–51.
16.Sage PT, Schildberg FA, Sobel RA, Kuchroo VK, Freeman GJ, Sharpe AH. Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function. Journal of immunology 2018; 200(8): 2592–602.
17.Kasagi S, Kawano S, Okazaki T, et al. Anti-programmed cell death 1 antibody reduces CD4+PD–1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. Journal of immunology 2010; 184(5): 2337–47.
18.Wong M, La Cava A, Singh RP, Hahn BH. Blockade of programmed death–1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease. Journal of immunology 2010; 185(11): 6563–71.
19.Wong M, La Cava A, Hahn BH. Blockade of programmed death–1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. Journal of immunology 2013; 190(11): 5402–10.
20.Zhou H, Xiong L, Wang Y, et al. Treatment of murine lupus with PD-LIg. Clinical immunology 2016; 162: 1–8.
21.Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. Journal of immunology 2000; 165(10): 5970–9.
22.Dorner T, Foster SJ, Farner NL, Lipsky PE. Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus. The Journal of clinical investigation 1998; 102(4): 688–94.
23.Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease. Annals of the rheumatic diseases 2008; 67 Suppl 3: iii83–6.
24.Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis and rheumatism 2008; 58(6): 1762–73.
25.Ma CS, Pittaluga S, Avery DT, et al. Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. The Journal of clinical investigation 2006; 116(2): 322–33.
26.Fecteau JF, Cote G, Neron S. A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. Journal of immunology 2006; 177(6): 3728–36.
27.Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. Journal of immunology 2007; 178(10): 6624–33.
28.Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and rheumatism 1997; 40(9): 1725.
29.Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy to adulthood. Clinical and experimental immunology 2010; 162(2): 271–9.
30.Wang X, Jiang Y, Zhu Y, et al. Circulating memory B cells and plasmablasts are associated with the levels of serum immunoglobulin in patients with ulcerative colitis. Journal of cellular and molecular medicine 2016; 20(5): 804–14.
31.Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus. Frontiers in immunology 2015; 6: 550.
32.Iwata S, Tanaka Y. B-cell subsets, signaling and their roles in secretion of autoantibodies. Lupus 2016; 25(8): 850–6.
33.Jia XY, Zhu QQ, Wang YY, et al. The role and clinical significance of programmed cell death- ligand 1 expressed on CD19(+)B-cells and subsets in systemic lupus erythematosus. Clinical immunology 2019; 198: 89–99.
34.Scharer CD, Blalock EL, Mi T, et al. Epigenetic programming underpins B cell dysfunction in human SLE. Nature immunology 2019; 20(8): 1071–82.
35.Jenks SA, Cashman KS, Zumaquero E, et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity 2018; 49(4): 725–39 e6.
36.Kubo S, Nakayamada S, Yoshikawa M, et al. Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. Arthritis & rheumatology 2017; 69(10): 2029–37.
37.Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD–1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmunity reviews 2013; 12(11): 1091–100.
38.Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439(7077): 682–7.
39.Day CL, Kaufmann DE, Kiepiela P, et al. PD–1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443(7109): 350–4.
40.Petrelli A, Mijnheer G, Hoytema van Konijnenburg DP, et al. PD–1+CD8+ T cells are clonally expanding effectors in human chronic inflammation. The Journal of clinical investigation 2018; 128(10): 4669–81.
41.Caielli S, Veiga DT, Balasubramanian P, et al. A CD4(+) T cell population expanded in lupus blood provides B cell help through interleukin–10 and succinate. Nature medicine 2019; 25(1): 75–81.
42.Gordon SR, Maute RL, Dulken BW, et al. PD–1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017; 545(7655): 495–9.
43.Thibult ML, Mamessier E, Gertner-Dardenne J, et al. PD–1 is a novel regulator of human B-cell activation. International immunology 2013; 25(2): 129–37.
44.McKay JT, Egan RP, Yammani RD, et al. PD–1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. Journal of immunology 2015; 194(5): 2289–99.
45.Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD–1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proceedings of the National Academy of Sciences of the United States of America 2001; 98(24): 13866–71.